MedTrace Logo

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

NCT04788472 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-10-17

No results posted yet for this study

Summary

Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia

Conditions

  • B-Cell Acute Lymphoblastic Leukemia, Adult

Interventions

DRUG

CAR-T cells targeting CD19 and CD22

Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion

Sponsors & Collaborators

  • Yake Biotechnology Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788472 on ClinicalTrials.gov